Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009–2013
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Though invasive aspergillosis (IA) complicates care of up to 13% of patients with immunocompromise, little is known about its morbidity and mortality burden in the United States. Methods: We analyzed the Health Care Utilization Project’s data from the Agency for Healthcare Research and Quality for 2009–2013. Among subjects with high-risk conditions for IA, IA was identified via International Classification of Diseases, Ninth Revision, Clinical Modification codes 117.3, 117.9, and 484.6. We compared characteristics and outcomes between those with (IA) and without IA (non-IA). Using propensity score matching, we calculated the IA-associated excess mortality and 30-day readmission rates, length of stay, and costs. Results: Of the 66634683 discharged patients meeting study inclusion criteria, 154888 (0.2%) had a diagnosis of IA. The most common high-risk conditions were major surgery (50.1%) in the non-IA and critical illness (41.0%) in the IA group. After propensity score matching, both mortality (odds ratio, 1.43; 95% confidence interval, 1.36–1.51) and 30-day readmission (1.39; 1.34–1.45) rates were higher in the IA group. IA was associated with 6.0 (95% confidence interval, 5.7–6.4) excess days in the hospital and $15542 ($13869–$17215) in excess costs per hospitalization. Conclusions: Although rare even among high-risk groups, IA is associated with increased hospital mortality and 30-day readmission rates, excess duration of hospitalization, and costs. Given nearly 40000 annual admissions for IA in the United States, the aggregate IA-attributable excess costs may reach $600 million annually.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laboratory diagnosis of invasive aspergillosis
Hope, W., Walsh, T., & Denning, D. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70238-3 · Cited by 495
Vallabhaneni, S., Benedict, K., Derado, G., & Mody, R. K. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw268 · Cited by 98
Zilberberg, M. D., Shorr, A. F., Huang, H., Chaudhari, P., Paly, V. F., & Menzin, J. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-310 · Cited by 62
Self-citationChang, D. C., Burwell, L. A., Lyon, G. M., Pappas, P. G., Chiller, T. M., Wannemuehler, K. A., Fridkin, S. K., & Park, B. J. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/524324 · Cited by 51 · cited 3×
“6, shown to be sensitive in detecting IA [12].”
BackgroundMethodResult
Cited by
Anti-infective Properties of the Golden Spice Curcumin
Praditya, D., Kirchhoff, L., Brüning, J., Rachmawati, H., Steinmann, J., & Steinmann, E. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00912 · Cited by 373
Let’s talk about sex characteristics—as a risk factor for invasive fungal diseases.
Egger, M., Hoenigl, M., Thompson, G. R., Carvalho, A., & Jenks, J. D. (2022) · Mycoses · doi:10.1111/myc.13449 · Cited by 82
Race and ethnicity: Risk factors for fungal infections?
Jenks, J. D., Aneke, C. I., Al-Obaidi, M. M., Egger, M., Garcia, L., Gaines, T., Hoenigl, M., & Thompson, G. R. (2023) · PLOS Pathogens · doi:10.1371/journal.ppat.1011025 · Cited by 55
“there was no statistical difference in the incidence of IA in different parts of the US after implementing propensity matching [81].”
BackgroundUpdate on invasive fungal infections in the Middle Eastern and North African region
Osman, M., Al Bikai, A., Rafei, R., Mallat, H., Dabboussi, F., & Hamze, M. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00325-x · Cited by 39
Metadata
- Authors
- Zilberberg, M. D., Nathanson, B. H., Harrington, R., Spalding, J. R., & Shorr, A. F.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-28
- Volume
- 67
- Issue
- 5
- Pages
- 727-735
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2801469916
- Cited by
- 62
- References
- 4
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.